LIPOXYGENASE INHIBITORS

Abstract: Novel compounds of the general formula where R′ is phenyl or methyl and R″ is fluorine or chlorine and their pharmaceutically acceptable salts are lipoxygenase inhibitors. They can be made into pharmaceutical composi­ tions for this purpose, possibly in conjunction with other active ingredients.

Description: LIPOXYGENASE INHIBITORS This invention relates to benzofuran compounds useful as lipoxygenase inhibitors. The 5-lipoxygenase enzyme controls the biosynthesis of the class of compounds known as leukotrienes. Inhibition of the 5-lipoxygenase enzyme therefore prevents or diminishes the adverse effects of the leukotrienes in a mammalian subject. The leukotrienes are a novel group of biologically active mediators derived from arachidonic acid through the action of the 5-lipoxygenase enzyme system. The leukotrienes play an important role in inducing allergic reactions, such as asthma, allergic bronchitis or allergic rhinitis in man. One of the leukotrienes (B4) contributes to both inflammation and allergic reactions in man. There are two groups of leukotrienes derived from a common unstable precursor, Leukotriene A4. The first of these are the peptido-lipid leukotrienes, the most important being Leukotrienes C4 and D4. These compounds collectively account for the biologically active materials known as the slow reacting substances of anaphylaxis. They are potent smooth muscle contracting agents, particularly on respiratory smooth muscle but also on other tissues (e.g. gall bladder). In addition, they promote mucous production, modulate vascular permeability changes and are potent inflammatory agents in human skin. The most important compound in the second group of leukotrienes is teukotriene B4, a dihydroxy -fatty acid derived from Leukotriene A4. This compound is a potent chemotactic agent for neutrolphils and eosinophils. When injected in vivo, in addition to promoting the accumulation of leukocytes, Leukotriene B4 is also a potent hyperalgesic agent and can modulate vascular permeability changes through a neutrophil-dependent mechanism. Both groups of leukotrienes are formed following oxygenation of arachidonic acid through the action of the 5-lipoxygenase enzyme. See D Bailey and F Casey, Ann. Rpts. Med. Chem. 17 203 (1982). Leukotrienes can also mediate other diseases. These include psoriasis, atopic dermatitis, gouty arthritis and gall bladder spasms. In addition, they may have a role in cardiovascular disease because Leukotrienes C4 and D4 act as coronary and cerebral arterial vasoconstrictors and these compounds may also have negative inotropic effects on the myocardium. In addition, the Leukotrienes are important mediators of inflammatory diseases through their ability to modulate leukocyte and lymphocyte function. See: B Samuelsson, Science-220 568 (1983). European Patent Specification EP-A-0 146 243 discloses inter alia pharmaceutical compositions containing compounds of the formula EMI2.1 ,e and their pharmaceutically acceptable salts, and the use of such compounds for inhibiting the biosynthesis of mammalian leukotrienes, and claims certain such compounds as novel. Among the values of the variables disclosed in EP-A-0 146 243 in the above formula are the following: X can be oxygen; Z can be a bond; R1 can be C16 alkyl; R2 can be C1-20 alkoxy or aryl- alkoxy); each of R3, R4, T and V, independently of the others, can be hydrogen, C1,6 alkyl, hydroxy or halogen. The present invention provides certain compounds that fall within the above formula, but are not specifically disclosed in EP-A-0 146 243. The compounds of the invention have the general formula EMI2.2 (Formula I) where R' is phenyl or methyl and R" is fluorine or chlorine or are pharmaceutically acceptable salts of such compounds. These compounds have been found to possess superior activity as lipoxygenase inhibitors compared with compounds specifically disclosed in EP-A-0 146 243. The compounds of Formula I may be used to treat or prevent mammalian (especially human) disease states such as erosive gastritis; erosive esophagitis; inflammatory bowel disease; ethanol-induced haemorrhagic erosions; hepatic ischemia; noxious-agent-induced damage or necrosis of hepatic, pancreatic, renal, or myocardial tissue; liver parenchymal damage caused by hepatoxic agents such as CC14 and D -galactosamine; ischemic renal failure; disease-induced hepatic damage; bile salt induced pancreatic or gastric damage; trauma- or stress-induced cell damage; and glycerol-induced renal failure. For this purpose the compounds are conveniently made up with pharmaceutical compositions. The pharmaceutical compositions of the present invention comprise a compound of formula I as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include sodium, potassium, lithium, ammonium, calcium, magnesium, ferrous, zinc, copper, manganous, aluminium, ferric and manganic salts. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ionexchange resins, such as isopropylamine, trimethylamine, diethylamine, t riethylam ine, tripropylam ine, ethanolam ine, 2-dimethylam inoethanol, 2diethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, Nethylpiperidine, N,Nldibenzylethylenediamine, morpheline, N-ethyl morpholine and polyamine resins. Compounds of the invention are potent inhibitors of the 5 lipoxygenase pathway of arachidonic acid metabolism and have little or no inhibiting effect on the cyclooxygenase pathway of arachidonic acid metabolism. The compounds of Formula I are active as inhibitors of the biosynthesis of both leukotriene B4, as well as leukotrienes C4, D4, E4 and F4, the active elements of slow reacting substance of anaphylaxis (SRS-A). This inhibition of the biosynthesis of leukotrienes indicates that the compositions areN useful to treat, prevent or ameliorate, in mammals and especially in humans, pulmonary conditions including diseases such as asthma; and allergies and allergic reactions such as allergic rhinitis, contact dermatitis, and allergic conjunctivitis. These compounds are also useful in mammals, especially in humans, as anti-inflammatory and analgesic agents; and in the treatment of skin diseases, such as psoriasis; and in the treatment of cardiovascular conditions, such as angina; and as cytoprotective agents. The cytoprotective activity of a compound may be observed in both animals and man by noting the increased resistance of the gastrointestinal mucosa to the noxious effects of strong irritants, for example, the ulcerogenic effects of aspirin or indomethacin. In addition to lessening the effect of non-steroidal anti-inflammatory drugs on the gastrointestinal tract, animal studies show that cytoprotective compounds will prevent gastric lesions induced by oral administration of strong acids, strong bases, ethanol, hypertonic saline solutions and the like. Two assays can be used to measure cyto-protective ability. These assays are; (A) an ethanol-induced gastric ulcer assay and (B) an indomethacin-induced ulcer assay. A. Ethanol-Induced Gastric Ulcer Twenty-four hour fasted Sprague-Dawley (S.D.) rats are perorally (p.o.) dosed with 1.0 ml absolute ethanol. Fifteen minutes prior to ethanol administration, groups of rats each receive either an aqueous vehicle (aqueous methylcellulose 5% wt.) or the test compound at various doses perorally. One hour later, the animals are killed and the stomach mucosae are examined for resulting lesions. B. Indomethacin-lnduced Ulcer Assay Indomethacin, 10 mg/kg p.o., is used to induce ulcers in 24 hour fasted S.D. rats. Fifteen minutes prior to indomethacin administration, groups of rats each receive either an aqueous vehicle (5% by weight methylcellulose) or the test compound at various doses perorally. Four hours later the animals are killed and the stomach mucosae are examined for resulting ulcers. The magnitude of a prophylactic or therapeutic dose of a compound of formula I will, of course, vary with the nature of the severity of the condition to be treated and with the particular compound of formula I and its route of administration. In general, the daily dose range for antiasthmatic, anti-allergic or anti-inflammatory use and, generally uses other than cytoprotection, lies within the range 10 lJg to 20 mg per kg body weight of a mammal, preferably from 50 vg to 10 mg per kg of body weight of a mammal, particularly 100 llg to 10 mg per kg of body weight of a mammal. The exact amount of a compound of the Formula I to be used as a cytoprotective agent will depend on, inter alia, whether it is being administered to heal damaged cells or to avoid future damage, on the nature of the damaged cells (e.g. gastro-intestminal ulcerations vs. nephrotic necrosis), and on the nature of the causative agent. An example of the use of a compound of the Formula I in avoiding future damage would be coadministration of a compound of the Formula I with a non-steroidal antiinflammatory drug (for example, indomethacin) that might otherwise cause such damage. For such use, the compound of Formula I is administered from 30 minutes prior up to 30 minutes after administration of the NSAID. Preferably, it is administered prior to or simultaneously with the NSAID (e.g. as a combination dosage form). The effective daily dosage level for compounds of Formula I inducing cyt op rot ect ion in mammals, especially humans, will generally range from 0.002 mg/kg to 100 mg/kg, preferably from 0.02 mg/kg to 30 mg/kg. The dosage may be administered in single or divided individual doses. Any suitable route of administration may provide a mammal, especially a human, with an effective dosage of a leukotriene antagonist. For example, administration may be oral, rectal, transdermal, parenteral, intramuscular or intravenous. Dosage forms include tablets, troches, dispersions, suspensions, solutions and capsules. The pharmaceutical compositions of the present invention comprise a compound of formula I as an active ingredient and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The compositions include compositions suitable for oral, rectal, ophthalmic, pulmonary, nasal, dermal, topical or parenteral (including subcutaneous, intramuscular and intravenous) administration, although the most suitable route in any given case will depend on the nature and severity of the conditions being treated and on the nature of the active ingredient. They may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy. For use where a composition for intravenous administration is employed, a suitable dosage range for anti-asthmatic, anti-inflammatory or anti-allergic use if from 0.01 to 20 mg (preferably from 0.1 to 10 mg) of a compound of formula I per kg of body weight per day and for cytoprotective use from 0.002 mg to 100 mg (preferably from 0.02 mg to 30 mg and especially from 0.1 mg to 10 mg) of a compound of Formula I per kg of body weight per day. In the case of an oral composition, a suitable dosage range for anti-asthmatic, antiinflammatory or anti-allergic use is, e.g. from 1 to 100 mg of a compound of formula I per kg of body weight per day, preferably from 5 to 40 mg per kg, and for cytoprotective use from 0.01 mg to 30 mg (preferably from 0.1 mg to 10 mg) of a compound of Formula I per kg of body weight per day. The topical application dosage forms include ointments, salves, controlled release patches, emulsions, solutions, thixotropic formulations, powders sprays and the like. For topical application, the percent by weight of the active ingredient (Formula I compound) may vary from 0.001 to 10%. For treating inflammation the mode of administration may be oral, parenteral, or by suppository. The various dosage forms are the same as those described above. For treating skin diseases such as psoriasis and atopic dermatitis, oral topical or parenteral administration is useful. For topical application to the diseased area, salves, patches, controlled-release patches and emulsions are convenient dosage forms. For use as an analgesic, i.e. for treating pain, administration may be, for example, oral, parenteral, by insufflation, or by suppository. For treating cardiovascular conditions, such as angina pectoris, any suitable mode of administration, e.g. oral, parenteral, topical or insufflation, and dosage form, e.g. pills, liquid formulations; controlledrelease capsules, or controlled-release skin patches, may be used. For administration by inhalation, the compounds of the present Invent ion are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser. The preferred composition for inhalation is a powder which may be formulated as a cartridge from which the powder composition may be inhaled with the aid of a suitable device. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. These inhalation formulations will range in dosage from 0.1 ug to 200 ug of a compound of Formula I, administered as necessary to provide relief. In practical use, leukotriene antagonists of Formula I can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or intravenous. In preparing the compositions for oral dosage, of the usual pharmaceutical media, e.g. water, glycols, oils, alcohols, flavouring agents, preservatives and colouring agents can be used for oral liquid preparations, e.g. suspensions, elixirs and solutions; or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders and disintegrating agents can be used for oral solid preparations, e.g. powders, capsules and tablets. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form. Tablets may be sugar coated or enteric-coated by standard techniques. In addition to the common dosage forms set out above, the leukotriene antagonists of Formula I may also be administered by controlled release means and/or delivery devices such as those described in U.S. Patents Nos. US-A-3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200 and 4,008,719. Pharmaceutical compositions of the present invention suitable for oral administration and by inhalation in the case of asthma therapy may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet may be prepared by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Desirably, each tablet contains from 25 mg to 500 mg of the active ingredient and each cachet or capsule contains from 25 to 500 mg of the active ingredient. The following are examples of representative pharmaceutical dosage forms for the compounds of Formula I: injectable Suspension mg/ml Leukotriene inhibitor 2 Methylcellulose 5.0 Tween 80 0.5 Benzyl alcohol 9.0 Methyl paraben 1.8 Propyl paraben 0.2 Water for injection to a total volume of 10 ml Tablet mg/tablet Leukotriene inhibitor 25 Microcrystalline Cellulose 415 Povidone 14.0 Pregelatinized Starch 43.5 Magnesium Stearate 2.5 500 Capsule mg/capsule Leukotriene inhibitor 25 Lactose Powder 573.5 Magnesium Stearate 1.5 600 In addition to the compounds of the invention, the pharmaceutical compositions can also contain other active ingredients, such as cyclooxygenase inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), and peripheral analgesic agents such as zomepirac and diflunisal. The weight ratio of the compound of the Formula I to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Thus, for example, when a compound of the Formula I is combined with an NSAID, the weight ratio of the compound of the Formula I to the NSAID will usually range from 1000:1 to 1:1000, preferably 200:1 to 1:200. Combinations of a compound of the Formula I and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used. Combinations of a compound of the invention and other active ingredients will usually be in the aforementioned ratios. NSAIDs can be characterized into five groups: (1) the propionic acid derivatives; (2) the acetic acid derivatives; (3) the fenamic acid derivatives; (4) the biphenylcarboxylic acid derivatives; and (5) the oxicams or pharmaceutically acceptable salts. The propionic acid derivatives which may be used comprise: ibuprofen, ibupruf en aluminium, indoprofen, ketoprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, t ioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid. Structurally related propionic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be included in this group. Thus, "propionic acid derivatives" as defined herein are non-narotic analgesics/non-steroidal anti-inflammatory drugs having a free -CH(CH3)COOH or -CH2CH2COOH group (which optionally can be in the form of a pharmaceutically acceptable salt group, e.g. -CH(CH3)COO Na+ or -CH2CH2COO Na+), typically attached directly or via a carbonyl function to a ring system, preferably to an aromatic ring system. The acetic acid derivatives which may be used comprise: indomethacin, which is a preferred NSAID, sulindac, tolmetin, zomepirac, diclofenac, fenclofenac, alclofenac, ibufenac, isoxepac, furofenac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, and fenclozic acid. Structurally related acetic acid derivatives having similar analgesic and antiinflammatory properties are also intended to be encompassed by this group. Thus, "acetic acid derivatives" as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs having a free -CH2COOH group (which optionally can be in the form of a pharmaceutically acceptable salt group, e.g. -CH2COO-Na+), typically attached directly to a ring system, preferably to an aromatic or heteroaromatic ring system. The fenamic acid derivatives which may be used comprise: mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid and tolfenamic acid. Structurally related fenamic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group. Thus, "fenamic acid derivatives" as defined herein are non-narcotic analgaesics/non-steroidal anti-inflammatory drugs which contain the basic structure: EMI10.1 which can bear a variety of substituents and in which the free -COOH group can be in the form of a pharmaceutically acceptable salt group, e.g. -COO Na+. The biphenylcarboxylic acid derivatives which can be used comprise: d iflunisal and flufenisal. Structurally related biphenylcarboxylic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group. Thus, "biphenylcarboxylic acid derivatives" as defined herein are nonnarcotic analgesics/non-steroidal and anti-inflammatory drugs which contain the basic structure: EMI11.1 which can bear a variety of substituents and in which the free -COOH group can be in the form of a pharmaceutically acceptable salt group, e.g. -COO Na+. The oxicams which can be used in the present invention comprise: piroxicam, sudoxicam, isoxicam and 4-hydroxyl-1,2-benzothiazine 1,1dioxide 4-(N-phenyl)-carboxam ide. Structurally relates oxicams having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group. Thus, "oxicams" as defined herein are non-narcotic analgesics/nonsteroidal anti-inflammatory drugs which have the general formula: EMI11.2 wherein R is an aryl or heteroaryl ring system. The following NSAIDs may also be used: acemetacin, alminoprofen, amfenac sodium, aminoprofen, anitrazafen, antrafenine, auranofin, bendazac lysinate, benzydamine, beprozin, broperamole, bufezolac, carprofen, cinmetacin, ciproquazone, clidanac, cloximate, dazidamine, deboxamet, delmetacin, detomidine, dexindoprofen, diacerein, di-fisalamine, difenpyramide, emorfazone, enfenam ic acid, enolicam, epirizole, et ersalat e, etodolac, etofenamate, fanetizole m esylat e, fenclofenac, fenclorac, fendosal, fenflumizole, fentiazac, feprazone, floctafenine, flunixin, - flunoxaprofen, fluproquazone, fopirtoline, fosfosal, furcloprofen, furofenac, glucametacin, guaimesal, ibuproxam, isofezolac, isonixim, isoprofen, isoxepac, isoxicam, lefetamine HC1, leflunomide, lofemizole, lonazolac calcium, lotifazole, loxoprofen, lysin clonixinate, meclofenamate sodium, meseclazone, miroprofen, nabumetone, nictindole, nimesulide, orpanoxin, oxametacin, oxapadol, oxaprozin, perisoxal citrate, pimeprofen, pimetacin, piproxen, pirazolac, pirfenidone, pirprofen, pranoprofen, proglumetacin maleate, proquazone, pyridoxiprofen, sudoxicam, suprofen, talmetacin, talniflumate, tenoxicam, thiazolinobutazone, thielavin B, tiaprofenic acid, tiaramide HCl, tiflamizole, timegadine, tioxaprofen, tolfenamic acid, tolpadol, tryptamid, ufenamate, and zidometacin. The following NSAIDs, designated by company code number, may also be used: 4801565, AA861, AD1491, AD1590, AFP802, AFP860, AHR6293, A177B, AP504, AU8001, BAY08276, BPPC, BW540C, BW755C, CHINOIN 127, CN100, C0893XX, CPP, D10242, DKA9, DV17, EB382, EGYT2829, EL508, F1044, FZ, GP53633, GP650, GV3658, 1iG13, ITCH, ITF, ITF182, KBl043, KC8973, KCNTEI6090, KME4, LA2851, LT696, LU20884, M7074, MED15, MG18311, MR714, MR897, MY309, NO164, ONO3144, PR823, PV102, PY108, QZ16, R830, R52131, RU16029, RU26559, RUB265, SCR152, SH440, S1R133, SIR 136, SIR92, SPAS51O, sQ27239, ST281, SX1032, SY6001, SaH46798, TA60, TAI901, To1615, TVX2706, TVX960, TZI615, U60257, UR2310, WY23205, WY41770, YM09561, YM13162, YS1033, and ZK31945. Finally, NSAIDs which may also be used include the salicylates, specifically aspirin, and the phenylbutazones, and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising the compounds of the invention may also contain other inhibitors of the biosynthesis of the leukotrienes. Pharmaceutical compositions comprising the compounds of the invention may also contain, as the second active ingredient, antihistaminic agents such as benadryl, dramamine, histadyl and phenergan. Alternatively, they may include prostaglandin antagonists such as those disclosed in European Patent Application EP-A-0 011 067 or thromboxane antagonists such as those disclosed in U.S. Patent Specification US-A-4,237,160. They may also contain histidine decarboxyase inhibitors such as a-fluoromethylhistidine, described in U.S. Patent Specification US-A-4,325,961. The compounds of the invention may also be advantageously combined with an H1 or H2-receptor antagonist, such as for instance cim et idine, ranitidine, terfenadine, famotidine, aminothiadiazoles and compounds such as those disclosed in U.S. Patents US-A-4,283,408, 4,362,736, 4,394,508 and European Patent Application EP-A-0 040 696. The pharmaceutical compositions may also contain a K+/H+ ATPase inhibitor such as omeprazole, which is disclosed in U.S. Patent US-A-4,255,431. The following Examples illustrate the preparation of the compounds of the present invention. EXAMPLE 1 2-Ethoxycarbonyl-3-methyl-4-hydroxy-5-propyl-7 -chlorobenzofuran Step A: Preparation of 2,6-dihydroxy-3-propyl-5-chloro-acetophenone A mixture of 2,6-dihydroxy-3-propylacetophenone (40 g, 0.206 mole) and N-chloro-succinimide (40 g; 0.300 mole) in methylene chloride (3 litres) was stirred at room temperature for two days. The reaction mixture was poured on a 3-litre fritted-disk funnel filled with silica gel and elution was carried out with methylene chloride. Evaporation of the filtrate yielded 0 2,6-dihydroxy-3-propyl-5-chloroacetophenone, m.p. 69-70 C. 1H NMR 0.93 (t, J=7 Hz, 3H, CH3), 1.63 (sextet, J=7 Hz, 2H, CH2), 2.53 (t, 5=7 Hz, 2H, CH2), 2.73 (s, 3H, CH3), CH2), 6.33 (s, 1H, proton ortho to chloro), 13.13 (s, 1H, OH). Step B: Preparation of 2-ethoxycarbonylm ethoxy-6-hydroxy-5-propyl-3 chloro-acetophenone A mixture of 2,6-dihydroxy-5-chloro-3-propylacetophenone (38.5 g, 0.169 mole), ethyl bromoacetate (18.6 ml; 0.169 mole) and potassium carbonate (23.24 g; 0.169 mole) in acetone (3 litres) was refluxed for 2.5 hours. The reaction mixture was filtered through diatomaceous earth and the filtrate was concentrated in vacuo to yield a residue that was purified by chromatography on silica gel and eluted with 5% ethyl acetate in hexane to yield 2-ethoxycarbonyl-m ethoxy-6-hydroxy-5-propyl-3- chloroacetophenone, m.p. 46-470C. 1 H NMR 0.93 (t, 5=7 Hz, 3H, CH3), 1.30 (t, 5=7 Hz, 3H, CH3, 1.63 (sextet, 5=7 Hz, 2H, CH2), 2.57 (t, 5=7 Hz, 2H, CH2), 2.77 (s, 3H, CH3), 4.27 (q, 5=7 Hz, 2H, CH2O), 4.73 (s, 2H, CH2), 7.23 (s, 1H, proton ortho to chloro), 12.50 (s, 1H, OH). Step C: Preparation of 2-ethoxycarbonyl-3-methyl-4-hydroxy-5-propyl chlorobenzofuran A solution of 2-ethaxycarbonylmethoxy-6-hydroxy-5-propyl-3-chloro- acetophenone (43 g; 0.136 mole) in freshly-distilled absolute ethanol (1.2 litre) was brought to reflux and a 1M solution of sodium ethoxide (273 ml; 0.273 mole) was added rapidly. The reaction mixture was refluxed for 1 hour. It was cooled to room temperature and poured into 0.5N hydrochloric acid and extracted with ethyl acetate. The organic phase was dried over Na2SO4 and concentrated in vacuo. The residue was chromatographed on silica gel and eluted with 15% ethyl acetate in hexane to yield 22.0 g of 2-ethoxycarbonyl-3-methyl-4-hydroxy-5-propyl-7- chlorobenzofuran, m.p. 165-1660C. H NMR 1.00 (t, 5=7 Hz, 3H, CH3), 1.25 (t, 5=7 Hz, 3H, CH3), 1.63 (sextet, 3=7 Hz, 2H, CH2), 2.57 (t, 5=7 Hz, 2H, CH2), 2.76 (s, 3H, CH3), 4.43 (q, 5=7 Hz, 2H, CH2O), 5.19 (s, 1H, OH), 7.15 (s, 1H, proton ortho to chloro). EXAMPLE 2 2-Ethoxycarbonyl-3-m ethyl-4-hydroxy-5-propyl-7-fluorobenzofuran Step A: Preparation of 2-hydroxy-6-allyloxyacetophenone A mixture of 2,6-dihydroxyacetophenone (300 g; 1.97 moles), potassium carbonate (271 g; 1.97 moles) and allyl bromide (271 ml; 2.25 moles) in acetone (10 litres) was refluxed for three hours. The reaction mixture was cooled, filtered through diatomaceous earth and concentrated in vacuo. The residue was chromatographed on silica gel using toluene as eluent to yield 305 g (80%) of 2-hydroxy-6 0 allyloxyacetophenone, m.p. 54-55 C. 1H NMR 2.40 (s, 3H, CH3), 4.57 (d, 5=6 Hz, 2H, OCH2), 5.57 (m, 1H, CH), 6.33 (m, 2H, CH2), 6.62 (d, J=9 Hz, 1H, proton ortho to hydroxyl), 6.83 (d, J=9 Hz, 1H, proton ortho to allyloxy), 7.72 (t, J=9 Hz, 1H, proton para to acetyl). Anal. Calcd. for CllH1203: C, 68.75; H, 6.25. Found: C, 68.66; H, 6.54 Step B: Preparation of 2,6-dihydroxy-3-allylacetophenone 2-Hydroxy-6-allyloxy-acetophenone (30 g; 0.156 mole) was heated under nitrogen at 1900C for 10 minutes. The mixture was cooled and slurried with carbon tetrachloride to yield quantitatively 2,6-dihydroxy-3allyl-acetophenone, m.p. 67-680C. lH NMR 2.77 (s, 3H, CH3), 3.37 (d, J=6 Hz, 2H, CH2), 5.37 (m, 1H, CH), 6.00 (m, 2H, CH2), 6.33 (d, J=9 Hz, 1H, proton ortho to hydroxyl), 7.17 (d, J=9 Hz, 1H, proton meta to hydroxy). Anal. Calcd. for CllHl203: C, 68.75; H, 6.25. Found: C, 68.90; H, 6.21. Step C: Preparation of 2,6-dihydroxy-3-propylacetophenone 2,6-dihydroxy-3-allyl-acetophenone (30 g; 0.156 mole) dissolved in ethanol (150 ml) was hydrogenated in a Parr apparatus in presence of 5% palladium on carbon. The catalyst was removed by filtration and the filtrate was concentrated to dryness to yield 30 gm of 2,6-dihydroxy-3 0 propylacetophenone, m.p. 76-78 C. H NMR 0.97 (t, 5=7 Hz, 3H, CH3), 1.60 (sextet, 3=7 Hz, 2H, CH2), 2.53 (t, J=7 Hz, 2H, CH2), 2.73 (s, 3H, CH3), 6.30 (d, J=9 Hz, 1H, proton ortho to hydroxy), 7.13 (d, J=9 Hz, 1H, proton meta to hydroxy). Anal. Calcd. for CllHl403: C, 68.04; H, 7.21. Found: C, 68.05; H, 7.34. Step D: Preparation of 2,6-dihydroxy-3-propyl-5-fluorn-acetophenone 1.) A solution of 2,6-dihydroxy-3-propylacetophenone (194 mg; 1 mmole) in fluorotrichloromethane (30 ml) was cooled to -780C and trifluoromethylhypofluorite was bubbled through the solution slowly, with monitoring of the reaction by TLC, until about half of the material had reacted. The mixture was poured onto a silica gel column and elution with 15% ethyl acetate in hexane gave 40 mg of 2,6-dihydroxy-3-propyl-5fluoroacetophenone. 1H NMR 0.93 (t, J=7 Hz, 3H, CH3), 1.67 (sextet, 3=7 Hz, 2H, CH2), 2.57 (t, J=7 Hz, 2H, CH2), 2.80 (s, 3H, CH3), 6.18 (d, 5=6 Hz, 1H, OH), 7.13 (d, J=ll Hz, 1H, proton ortho to fluoro). 2a.) Preparation of 2,6-dim ethoxy-3-propyl-5-fluoroacetophenone. A solution of 2,6-dimethoxy-3-propylacetophenone (21.0 g; 94.6 mmoles) in fluorotrichloromethane (30 ml) was cooled at -78 0C and trifluoromethylhypofluorite was bubbled through the solution slowly. The reaction was monitored by TLC until about 75% of the material had reacted. The mixture was poured onto a silica gel column and elution with 15% ethyl acetate in hexane gave 11.1 g of 2,6-dimethexy-3-propyl-5- fluoroacetophenone and 9.0 g of unreacted 2,6-dimethoxy-3propylacetophenone. 1H NMR 0.97 (t, 5=7 Hz, 3H, CH3), 1.67 (sextet, 5=7 Hz, 2H, CH2), 2.50 (t, 3=7 Hz, 2H, CH2), 2.50 (s, 3H, CH3), 3.70 (s, 3H, CH3), 3.82 (d, 3=3 Hz, 3H, CH3), 6.90 (d, 3=11 Hz, 1H, proton ortho to fluoro). 2b.) Preparation of 2,6-dihydroxy-3-propyl-5-f luoroacetophenone To a solution of 2,6-dimethoxy-3-propyl-5-îluoro-acetophenone 0 (3.0 g; 12.5 mmoles) in methylene chloride (32 ml) cooled to -78 C, was added dropwise over I hour a 1M solution of boron tribromide (56 ml; 56 mmoles). The temperature was allowed to rise to room temperature and 0 the reaction mixture was stirred for 3 hours. It was then cooled to -78 C and methanol (20 ml) was added rapidly. The resulting solution was poured in water, the phases were separated and the aqueous phase was extracted with methylene chloride. The organic phases were combined, washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was chromatographed on silica gel and eluted with 7% ethyl acetate in hexane to yield 1.5 g (58%) of 2,6-dihydroxy-3-propyl-5-fluoroacetophenone. H NMR 0.93 (t, J=7 Hz, 3H, CH3), 1.63 (sextet, 5=7 Hz, 2H, CH2), 2.50 (t, 3=7 Hz, 2H, CH2), 2.73 (s, 3H, CH3), 5.93 (d, 3=6 Hz, 1H, OH), 7.10 (d, J=ll Hz, 1H, proton ortho to fluoro). Step E: Preparation of 2-ethoxycarbonylmethoxy-6-hydroxy-5-prop fluoroacetophenone A mixture of 2,6-dihydroxy-S4luoro-3-propylacetophenone (3.5 g, 16.5 mmoles), ethyl bromoacetate (2.0 ml; 18.1 mmoles) and potassium carbonate (2.27 g; 16.5 mmoles) in acetone (1 litre) was refluxed for a period of 0.5 hour. The reaction mixture was filtered through diatomaceous earth and the filtrate was concentrated in vacuo to yield a residue that was purified by chromatography on silica gel and eluted with 10% ethyl acetate in hexane to yield 4.2 g (86%) of 2-ethoxycarbonylmethoxy-6-hydroxy-5- propyl-3-fluoroacetophenone. 1H NMR 0.93 (t, J=7 Hz, 3H, CH3), 1.27 (t, J=7 Hz, 3H, CH3), 1.63 (sextet, 3=7 Hz, 2H, CH2), 2.53 (t, 3=7 Hz, 2H, CH2), 2.77 (s, 3H, CH3), 4*20 (q, 3=7 Hz, 2H, CH2O), 4.80 (s, 2H, CH2), 7.03 (d, 3=11 Hz, 1H, proton ortho to fluoro). Step F: Preparation of 2-ethoxyearbonyl-3-methyl-4-hydroxy-5-propyl-7- fluorobenzofuran A solution of 2-ethoxycarbonylmethoxy 6-hydroxy-5-propyl-3- fluoroacetophenone (15 g; 50.0 mmoles) in freshly-distilled absolute ethanol (0.5 litre) was brought to reflux and a 1M solution of sodium ethoxide (100 ml; 100 mmoles) was added rapidly. The reaction mixture was refluxed for a period of 1 hour. It was cooled to room temperature and poured into 0.5N hydrochloric acid and extracted with ethyl acetate. The organic phase was dried over Na2SO4 and concentrated in vacuo. The residue was chromatographed on silica gel and eluted with 10% ethyl acetate in hexane to yield 9.0 g of 2-ethoxycarbonyl-3-methyl-4-hydroxy-5- propyl-7-fluorobenzofuran. 1H NMR 1.00 (t, 3=7 Hz, 3H, CH3), 1.43 (t, J=7 Hz, 3H, CH3), 1.63 (sextet, 5=7 Hz, 2H, CH2), 2.57 (t, 5=7 Hz, 2H, CH2), 2.80 (s, 3H, CH3), 4.47 (q, 5=7 Hz, 2H, CH2O), 4.97 (s, 1H, OH), 6.90 (s, 1H, proton ortho to fluoro). EXAMPLE 3 Benzyl 3-m ethyl-4-hydroxy-5-propyl-7-chlorobenzofuran-2-carboxylate A mixture of 3-methyl-4-hydroxy-5-propyl-7-chlorobenzofuran-2- carboxylic acid (0.5 g; 1.9 mmole), potassium carbonate (0.26 g; 1.9 mmole) and benzyl bromide (0.22 ml; 1.9 mmole) in acetone (100 ml) was refluxed for 2 hours. The solids were filtered off and the filtrate was concentrated in vacuo. The residue was chromatographed on silica gel and eluted with 15% ethyl acetate in hexane to yield 200 mg (30%) of benzyl 3-methyl-4hydroxy-5-propyl-7-chlorobenzofuran-2-carboxylate, m .p. 119 - 120 0C. 1H NMR: 0.97 (t, 5=7 Hz, 3H, CH3), 1.60 (sextet 3=7 Hz, 2H, CH2), 2.53 (t, 5=7 Hz, 2H, CH2), 2.73 (s, 3H, CH3), 5.10 (s, 1H, OH), 5.43 (s, 2H, CH2), 7.10 (s, 1H, H6), 7.40 (m, 5H, aromatic protons). EXAMPLE 4 Benzyl 3-methyl-4-hydroxy-5-propyl-7-fluorobenzofuran-2-carboxylate By using 3 -methyl-4-hydroxy-5-propyl-7-fluorobenzofuran-2 carboxylic acid in place of 3-methyl-4-hydroxy-5-propyl-7chlorobenzofuran-2-carboxylic acid and following the procedure of Example 3, the compound mentioned in the title is obtained.

Claims: CLAIMS 1. A compound having the general formula EMI18.1 (Formula I) where R' is phenyl or methyl and R" is fluorine or chlorine or a pharmaceutically acceptable salt of such a compound. 2. 2-Ethoxycarbonyl-3-methyl-4-hydroxy-5-propyl-7-chlorobenzofuran. 3. 2-Ethoxycarbonyl-3-m ethyl-4-hydroxy-5-propyl-7-fluorobenzofuran. 4. Benzyl 3-methyl-4-hydroxy-5-propyl-7-chlorobenzofuran-2carboxylate. 5. Benzyl 3-m ethyl-4-hydroxy-5-propyl-7 -fluorobenzofuran-2carboxylate. 6. A pharmaceutical composition containing as the or an active ingredient a compound as claimed in any one of Claims 1 to 5. 7. A composition as claimed in Claim 6 additionally comprising an effective amount of a second active ingredient that is a non-steroidal antiinflammatory drug; a peripheral analgesic agent; a cyclooxygenase inhibitor; a leukotriene antagonist; an antihistaminic agent; a prostaglandin antagonist or a thromboxane antagonist. 8. A composition as claimed in Claim 7 in which the second active ingredient is indomethacin. 9. A compound as claimed in any one of Claims 1 to 5 or a composition as claimed in any one of Claims 6 to 8 for use in a method of therapeutic treatment of humans or other mammals. 10. A compound as claimed in any one of Claims 1 to 5 or a composition as claimed in any one of Claims 6 to 8 for use in a method of (a) inhibiting mammalian leukotriene biosynthesis or action; (b) treating pulmonary conditions; (c) treating inflammation; (d) treating allergies; (e) treating pain; (f) treating cardiovascular conditions; or (g) treating skin conditions in a mammal, especially a human.

Inventors: ATKINSON, JOSEPH G., GUINDON, YVAN, LAU, CHEUK K.
Applicants: MERCK FROSST CANADA INC.
Application year: 1986
Main classification: C07D307
IPC codes: C07D307, C12N9, A61P37, A61P11, A61P29, A61P43, A61K31, A61P1